133 related articles for article (PubMed ID: 31658275)
1. Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.
Maahs L; Sanchez BE; Gupta N; Van Harn M; Barrack ER; Reddy PV; Hwang C
PLoS One; 2019; 14(10):e0222510. PubMed ID: 31658275
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
3. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.
Zhu S; Ni Y; Sun G; Wang Z; Chen J; Zhang X; Zhao J; Zhu X; Dai J; Liu Z; Liang J; Zhang H; Zhang Y; Shen P; Zeng H
Cancer Med; 2021 Sep; 10(18):6282-6290. PubMed ID: 34318630
[TBL] [Abstract][Full Text] [Related]
4. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
6. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
9. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
11. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
12. ERG induces taxane resistance in castration-resistant prostate cancer.
Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
14. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
16. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
17. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
[TBL] [Abstract][Full Text] [Related]
19. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
20. JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.
Cai X; Duan X; Tang T; Cui S; Wu T
BMC Cancer; 2023 May; 23(1):423. PubMed ID: 37165308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]